Progress of autologous hematopoietic stem cell transplantation and chimeric antigen receptor T-cell therapy for treatment of relapsed/refractory large B-cell lymphoma / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
; (12): 65-67, 2022.
Artigo
em Chinês
| WPRIM (Pacífico Ocidental)
| ID: wpr-929734
Biblioteca responsável:
WPRO
ABSTRACT
Large B-cell lymphoma (LBCL) is the most common lymphoma subtype in China. Although the application of immuno-chemotherapy has significantly improved the cure rate, 40%-50% of patients will still experience refractory or relapse. Conventional salvage chemotherapy followed by autologous hematopoietic stem-cell transplantation (AHCT) can cure about 40% of chemotherapy-sensitive relapsed/refractory LBCL patients, but about 50% of relapsed/refractory LBCL patients cannot undergo AHCT because of resistance to salvage immunotherapy. Chimeric antigen receptor T-cell (CAR-T) immunotherapy has attracted much attention, and two CD19 CAR-T products have been approved in China for the treatment of relapsed/refractory LBCL. At the 63rd American Society of Hematology Annual Meeting, several international phase 3 trials reported the latest progress of CAR-T and AHCT in the treatment of relapsed/refractory LBCL.
Texto completo:
Disponível
Base de dados:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Journal of Leukemia & Lymphoma
Ano de publicação:
2022
Tipo de documento:
Artigo